Esperion Therapeutics, Inc. (ESPR) SEC Filings — 2025
17 SEC filings for Esperion Therapeutics, Inc. (ESPR) in 2025.
Filings
- Esperion's Net Loss Widens to $84.5M Despite Strong Product Sales Growth — 10-Q · Nov 6, 2025
- Esperion Therapeutics, Inc. 8-K Filing — 8-K · Nov 4, 2025
- Esperion Therapeutics Enters Material Definitive Agreement — 8-K · Oct 8, 2025
- Esperion Therapeutics Files 8-K — 8-K · Oct 7, 2025
- Esperion's Q2 Product Sales Soar, But Collaboration Revenue Plummets — 10-Q · Aug 13, 2025
- Esperion Therapeutics Files 8-K Amendment — 8-K/A · Aug 11, 2025
- Esperion Therapeutics Files 8-K on Financials — 8-K · Aug 5, 2025
- Esperion Therapeutics Appoints New CMO, Director — 8-K · Jul 1, 2025
- Esperion Therapeutics Files 8-K: Director Changes & Compensation Updates — 8-K · Jun 2, 2025
- Esperion Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025
- Esperion Therapeutics Files 8-K on Financials — 8-K · May 6, 2025
- Esperion Therapeutics DEF 14A: Executive Pay Details — DEF 14A · Apr 17, 2025
- Esperion Therapeutics Files 8-K on Officer/Director Changes — 8-K · Apr 4, 2025
- Esperion Therapeutics Files 8-K on Director Changes and Compensation — 8-K · Apr 1, 2025
- Esperion Therapeutics Files 2024 10-K — 10-K · Mar 7, 2025
- Esperion Therapeutics Files 8-K — 8-K · Mar 4, 2025
- Esperion Therapeutics Files 8-K on Financials — 8-K · Jan 16, 2025